Gradient Investments’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Gradient Investments’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-375	Closed	-$10.3K	–	1563
2022 Q4	$10.3K	Buy	+375	New	+$9.98K	﹤0.01%	803

Other funds holding FTXH

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

WFA

WMG Financial Advisors Knoxville, Tennessee $265M AUM 26.03% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

KNW

Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $383M AUM 36.18% 1-Year Est. Return

Gradient Investments's FTXH Position: Q1 2023 in Review

Gradient Investments sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2023, closing a stake of 375 shares — an estimated $10.3K sold.

Gradient Investments first reported a position in FTXH in Q4 2022 and held it in 1 quarter. The position peaked at $10.3K in Q4 2022. 31 funds tracked by Wall St. Rank hold FTXH as of Q1 2023.

Gradient Investments reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2023 after selling out during the quarter.
Gradient Investments sold 375 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2023, an estimated $10.3K.
Gradient Investments first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2022 and held it in 1 quarter.
Gradient Investments's First Trust Nasdaq Pharmaceuticals ETF position peaked at $10.3K in Q4 2022.
31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2023.

Based on Gradient Investments's 13F filing for Q1 2023, filed 17 Apr 2023.